Ganda OP, et al. - Researchers evaluated the efficacy and safety of alirocumab (a PCSK9 inhibitor) among 984 patients with diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD). Data were pooled from nine ODYSSEY phase 3 trials centered on this patient population. Via analyzing changes in low-density lipoprotein cholesterol (LDL-C) and other lipids from baseline to Week 24 (intention-to-treat) in four pools by alirocumab dosage (150 mg every 2 weeks [150] or 75 mg with possible increase to 150 mg every 2 weeks [75/150]), control (placebo/ezetimibe) and background statin usage (yes/no), they identified significantly reduced LDL-C and other atherogenic lipid parameters in association with alirocumab. Furthermore, alirocumab was well tolerated in persons with DM and ASCVD.